Rankings
▼
Calendar
▼
SION Q1 2024 Earnings Report — Sionna Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
Sionna Therapeutics, Inc.
SION
Q1 2024 Earnings
Reported March 31, 2024
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Free Cash Flow
Metric
Q1 2024
Q4 2023
Q1 2023
QoQ Change
YoY Change
Revenue
$0
$0
—
—
—
Op. Income
-$13M
-$13M
—
-4.4%
—
EPS (Diluted)
$-0.27
$-0.27
—
0.3%
—
Free Cash Flow
-$13M
-$8M
—
-74.0%
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$10M
Selling & Marketing
$0
General & Administrative
$3M
SG&A Expenses
$3M
Other Expenses
$366.0K
Operating Expenses
$13M
Cost & Expenses
$13M
OPERATING INCOME
-$13M
Interest Income
$1M
Interest Expense
$0
Other Income/Expenses
$1M
INCOME BEFORE TAX
-$12M
Income Tax Expense
$0
NET INCOME
-$12M
D&A
$366.0K
EBIT
-$13M
EBITDA
-$13M
EPS
-$0
EPS Diluted
-$0
marketcaparena.com
Cash Flow Statement
Item
Amount
Net Income
-$12M
Depreciation & Amortization
$166.0K
Stock-Based Compensation
$647.0K
Deferred Income Tax
$0
Other Non-Cash Items
$381.0K
Change in Working Capital
-$3M
OPERATING CASH FLOW
-$13M
Capital Expenditure
$0
Acquisitions (Net)
$0
Purchases of Investments
-$124M
Sales/Maturities of Investments
$0
Other Investing Activities
$0
NET CASH FROM INVESTING
-$124M
Net Debt Issuance
$0
Common Stock Repurchased
$0
Common Dividends Paid
$0
Other Financing Activities
$5.0K
NET CASH FROM FINANCING
$181M
FREE CASH FLOW
-$13M
Net Change in Cash
$44M
marketcaparena.com
← FY 2024
SION Overview
Q2 2024 →
